Literature DB >> 22688626

Bone: the conundrum of glucocorticoid-induced osteoporosis.

Steven L Teitelbaum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22688626     DOI: 10.1038/nrendo.2012.89

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?

Authors:  Steven L Teitelbaum; Margaret P Seton; Kenneth G Saag
Journal:  Arthritis Rheum       Date:  2011-02

Review 2.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Jennifer M Grossman; Rebecca Gordon; Veena K Ranganath; Chad Deal; Liron Caplan; Weiling Chen; Jeffrey R Curtis; Daniel E Furst; Maureen McMahon; Nivedita M Patkar; Elizabeth Volkmann; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-26       Impact factor: 4.794

3.  Glucocorticoids suppress bone formation via the osteoclast.

Authors:  Hyun-Ju Kim; Haibo Zhao; Hideki Kitaura; Sandip Bhattacharyya; Judson A Brewer; Louis J Muglia; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

4.  Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.

Authors:  R S Weinstein; R L Jilka; A M Parfitt; S C Manolagas
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

Review 5.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

6.  Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

Authors:  J D Adachi; K G Saag; P D Delmas; U A Liberman; R D Emkey; E Seeman; N E Lane; J M Kaufman; P E Poubelle; F Hawkins; R Correa-Rotter; C J Menkes; J A Rodriguez-Portales; T J Schnitzer; J A Block; J Wing; H H McIlwain; R Westhovens; J Brown; J A Melo-Gomes; B L Gruber; M J Yanover; M O Leite; K G Siminoski; M C Nevitt; J T Sharp; M P Malice; T Dumortier; M Czachur; W Carofano; A Daifotis
Journal:  Arthritis Rheum       Date:  2001-01

Review 7.  Glucocorticoid-induced osteoporosis: an update.

Authors:  Gherardo Mazziotti; Alberto Angeli; John P Bilezikian; Ernesto Canalis; Andrea Giustina
Journal:  Trends Endocrinol Metab       Date:  2006 May-Jun       Impact factor: 12.015

8.  Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Authors:  Kenneth G Saag; Elizabeth Shane; Steven Boonen; Fernando Marín; David W Donley; Kathleen A Taylor; Gail P Dalsky; Robert Marcus
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

9.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

Authors:  T P Van Staa; R F Laan; I P Barton; S Cohen; D M Reid; C Cooper
Journal:  Arthritis Rheum       Date:  2003-11

10.  Matrix-embedded cells control osteoclast formation.

Authors:  Jinhu Xiong; Melda Onal; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Nat Med       Date:  2011-09-11       Impact factor: 53.440

  10 in total
  7 in total

1.  The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.

Authors:  H Sato; N Kondo; Y Wada; T Nakatsue; S Iguchi; J Fujisawa; J J Kazama; T Kuroda; M Nakano; N Endo; I Narita
Journal:  Osteoporos Int       Date:  2015-10-30       Impact factor: 4.507

2.  miR-27a promotes osteogenic differentiation in glucocorticoid-treated human bone marrow mesenchymal stem cells by targeting PI3K.

Authors:  Jinshan Tang; Huaixi Yu; Yunqing Wang; Gang Duan; Bin Wang; Wenbo Li; Ziqiang Zhu
Journal:  J Mol Histol       Date:  2021-02-02       Impact factor: 2.611

3.  Smad4 is required to inhibit osteoclastogenesis and maintain bone mass.

Authors:  Mayu Morita; Shigeyuki Yoshida; Ryotaro Iwasaki; Tetsuro Yasui; Yuiko Sato; Tami Kobayashi; Ryuichi Watanabe; Takatsugu Oike; Kana Miyamoto; Masamichi Takami; Keiko Ozato; Chu-Xia Deng; Hiroyuki Aburatani; Sakae Tanaka; Akihiko Yoshimura; Yoshiaki Toyama; Morio Matsumoto; Masaya Nakamura; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

4.  miR-365 Ameliorates Dexamethasone-Induced Suppression of Osteogenesis in MC3T3-E1 Cells by Targeting HDAC4.

Authors:  Daohua Xu; Yun Gao; Nan Hu; Longhuo Wu; Qian Chen
Journal:  Int J Mol Sci       Date:  2017-05-04       Impact factor: 5.923

5.  Bone remodeling serum markers in children with systemic lupus erythematosus.

Authors:  Sheng Hao; Jing Zhang; Bingxue Huang; Dan Feng; Xiaoling Niu; Wenyan Huang
Journal:  Pediatr Rheumatol Online J       Date:  2022-07-27       Impact factor: 3.413

6.  Potential antiosteoporotic agents from plants: a comprehensive review.

Authors:  Min Jia; Yan Nie; Da-Peng Cao; Yun-Yun Xue; Jie-Si Wang; Lu Zhao; Khalid Rahman; Qiao-Yan Zhang; Lu-Ping Qin
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-31       Impact factor: 2.629

7.  COL3A1, COL6A3, and SERPINH1 Are Related to Glucocorticoid-Induced Osteoporosis Occurrence According to Integrated Bioinformatics Analysis.

Authors:  Liuxun Li; Meiling Yang; Anmin Jin
Journal:  Med Sci Monit       Date:  2020-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.